ANGN Angion Biomedica Corp.

Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]

US | NASDAQ | Stock

Price: $0.6728

Decreased by -1.45%
Dollar Volume: 102.02 K
ADR%: 9.37
Earnings Report Date (estimate): Mar 28, 23 (-0.21)

Market Cap.: 20.26 M
Shares Float: 20.46 M
Shares Outstanding: 30.11 M

Beta: 0.00
Price / Earnings: -0.63
BPR: 5.35

20D Range: 0.59 1.02
50D Range: 0.59 1.02
200D Range: 0.59 2.04

Quarterly Earnings
Annual Earnings

Reported Date	EPSChange YoY	EstimateSurprise
Nov 17, 22	-0.30 Decreased by -151.72%	-0.36 Increased by +16.67%
Nov 14, 22	-0.30 Increased by +43.40%	-0.36 Increased by +16.67%
Aug 15, 22	-0.30 Increased by +48.28%	-0.46 Increased by +34.78%
May 16, 22	-0.48 Increased by +69.23%	-0.43 Decreased by -11.63%
Mar 30, 22	0.58 Increased by +130.53%	-0.62 Increased by +193.55%
Nov 12, 21	-0.53	-0.72 Increased by +26.39%
Aug 12, 21	-0.58	-0.69 Increased by +15.94%
May 17, 21	-1.56	-0.62 Decreased by -151.61%

Quarterly Financials
Annual Financials

Fiscal ending date	RevenueChange YoY	IncomeChange YoY	ProfitChange YoY
Sep 30, 22	0.00 Decreased by -100.00%	-8.99 M Increased by +42.77%	Decreased by N/A% Decreased by N/A%
Jun 30, 22	653.00 K Increased by +20.93%	-9.14 M Increased by +46.47%	Decreased by -1.40 K% Increased by +55.73%
Mar 31, 22	1.65 M Increased by +344.20%	-14.24 M Increased by +61.19%	Decreased by -864.08% Increased by +91.26%
Dec 31, 21	25.94 M Increased by +5.55 K%	14.89 M Increased by +151.57%	Increased by +57.40% Increased by +100.91%
Sep 30, 21	1.46 M Increased by +76.54%	-15.70 M Increased by +11.12%	Decreased by -1.08 K% Increased by +49.66%
Jun 30, 21	540.00 K Decreased by -25.93%	-17.07 M Increased by +16.07%	Decreased by -3.16 K% Decreased by -13.30%
Mar 31, 21	371.00 K Decreased by -57.11%	-36.69 M Decreased by -177.47%	Decreased by -9.89 K% Decreased by -546.93%
Dec 31, 20	459.00 K Decreased by -34.05%	-28.88 M Decreased by -80.30%	Decreased by -6.29 K% Decreased by -173.40%

Top 20 ETF Stock Exposure
Top 20 Institutional Holders
Top 20 Mutual Fund Holders

Rank	ETF	Shares	Market Value	Weight % in ETF

DAILY

WEEKLY

MONTHLY

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.